Research & Development
Innovative Health Diagnostics Launches New Platform, Marrying Digital Health Services and Diagnostics to Create Accessible and Personalized At-Home Healthcare
22 September 2022 - - US-based CLIA- and FDA-certified lab Innovative Health Diagnostics (IHD) has launched its Diagnostics as a Service platform, giving brands the ability to provide their patients with access to at-home healthcare at any time and anywhere, the company said.

Digital health and healthcare DTC entities - including fertility clinics, OBGYNs, primary care providers and pharmacies - can utilize IHD's partner platform to offer consumers over 70 different at-home tests, from infectious disease and wellness to women's and men's health.

The platform bridges the gap between digital health services and diagnostics - creating a more complete customer experience with emphasis on fast turnaround times, actionable results, and superior customer service provided by IHD.

Accelerating at-home testing services for healthcare companies, IHD's new platform enables a better customer experience and outcomes, seamless technology integration, and custom kits built specifically for the unique mix of tests required by the partner and its patients.

IHD's health partners can leverage the company's end-to-end DaaS platform or select individual modules that fit into the brand's existing operation, such as logistics and clinical networks.

IHD serves as a collaborative and flexible partner while maintaining the highest standards of testing methodologies, quick turnaround times and affordability.

Innovative Health Diagnostics empowers every person by providing access to accurate, clinical testing, when and where it matters most. IHD services also include fertility and in vitro fertilization testing; FDA donor testing for families completing surrogacies; and COVID-19 polymerase chain reaction and antibody testing.